European Commission approves Lenvima + Keytruda to treat endometrial carcinoma – Eisai + Merck Inc.
Eisai Co., Ltd. and Merck Inc., announced that the European Commission has approved the combination of Lenvima, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai,… read more.
